^[1] Excluding estimated revenue growth related to SARS-CoV-2 contribution (testing revenue net of attrition impact) ^[2] ESG report: Our medical excellence for you - your access to the most innovative laboratory services | SYNLAB ^[3] Please refer to the Appendix regarding the use of SYNLAB and SYNLAB Group in this press release. ^[4] Attrition impact on revenue from confinement measures, such as closures of blood collection points or patients delaying non-critical medical care, that resulted in temporary decreases in ordinary testing volumes ^[5] As defined in Appendix ^[6] As defined in Appendix ^[7] Belgium, Nordics -----------------------------------------------------------------------------------------------------------------------

2021-05-12 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de ----------------------------------------------------------------------------------------------------------------------- 


Language:     English 
Company:      SYNLAB AG 
              Moosacher Straße 88 
              80809 Munich 
              Germany 
Phone:        +49 1701183753 
E-mail:       ir@synlab.com 
Internet:     www.synlab.com/ 
ISIN:         DE000A2TSL71 
WKN:          A2TSL7 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1195495 
 
End of News   DGAP News Service 
=------------

1195495 2021-05-12


 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1195495&application_name=news

(END) Dow Jones Newswires

May 12, 2021 01:31 ET (05:31 GMT)